Tauroursodeoxycholic acid

DRUG12 trials

Sponsors

Children's Hospital Medical Center, Cincinnati, Washington University School of Medicine, The First Affiliated Hospital of Guangzhou Medical University, University of Missouri-Columbia, Johns Hopkins University

Conditions

Amyotrophic Lateral SclerosisAmyotrophic Lateral Sclerosis (ALS)AsthmaCholestasisCystic FibrosisDiabetesDiabetes Mellitus, Type 2Endoplasmic Reticulum Stress

Early Phase 1

The Clinical Application of Tauroursodeoxycholic Acid in Patients With Liver Fibrosis.

The First Affiliated Hospital with Nanjing Medical UniversityLiver Cirrhosis

Start: 2021-03-05End: 2021-07-30Target: 60Updated: 2021-03-09

Phase 1

A Trial of Bile Acid Supplementation in Patients With Multiple Sclerosis

CompletedNCT03423121

Johns Hopkins UniversityProgressive Multiple Sclerosis

Start: 2018-06-19End: 2022-07-05Updated: 2023-05-03

Trial of Tauroursodeoxycholic Acid (TUDCA) in Asthma

TerminatedNCT03878654

University of VermontAsthma

Start: 2019-01-10End: 2019-09-11Updated: 2019-09-16

Phase 3

Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS

Humanitas Mirasole SpAAmyotrophic Lateral Sclerosis (ALS)

Start: 2019-02-22End: 2023-12-31Updated: 2023-07-10

Open Label Extension of TUDCA-ALS Study

Humanitas Mirasole SpAAmyotrophic Lateral Sclerosis

Start: 2021-10-25End: 2025-03-31Target: 184Updated: 2023-03-03

Phase 4

The Discovery of the Double Sphincter in Gallbladder

The First Affiliated Hospital of Guangzhou Medical UniversityGallstone

Start: 2012-12-31End: 2018-12-31Target: 150Updated: 2016-03-08

Unknown Phase

Randomized Study of Tauroursodeoxycholic Acid in Prophylactic Therapy of Total Parenteral Nutrition Associated Cholestasis in Infants

CompletedNCT00004410

Children's Hospital Medical Center, CincinnatiCholestasis

Start: 1998-06-30End: 2002-03-31Target: 50Updated: 2015-03-25

Study of Tauroursodeoxycholic Acid for Hepatobiliary Disease in Cystic Fibrosis

CompletedNCT00004441

Children's Hospital Medical Center, CincinnatiCystic Fibrosis

Start: 1997-09-30End: 2001-09-30Target: 39Updated: 2015-03-25

Effect of Endoplasmic Reticulum Stress on Metabolic Function

CompletedNCT00771901

Washington University School of MedicineDiabetes, Insulin Resistance, Obesity

Start: 2008-02-29End: 2014-12-31Updated: 2018-05-29

Tauroursodeoxycholic Acid for Protease-inhibitor Associated Insulin Resistance

CompletedNCT01877551

Washington University School of MedicineEndoplasmic Reticulum Stress, HIV Related Insulin Resistance, Protease Inhibitor Related Insulin Resistance

Start: 2013-09-30End: 2018-05-31Updated: 2020-01-27

Effects of Dietary Supplement Tauroursodeoxycholic Acid on Vascular Function

CompletedNCT03331432

University of Missouri-ColumbiaType 2 Diabetes Mellitus

Start: 2015-10-28End: 2018-02-14Updated: 2018-02-19

Effects of TUDCA on Endothelial Function in Type 2 DM

TerminatedNCT03462940

Boston UniversityDiabetes Mellitus, Type 2, Endothelial Dysfunction, Insulin Response

Start: 2018-04-02End: 2021-02-09Updated: 2021-03-24

Related Papers

A randomized double-blind clinical trial on safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS): the statistical analysis plan of TUDCA-ALS trial.

2023-12-055 citations

Tauroursodeoxycholic acid in patients with amyotrophic lateral sclerosis: The TUDCA-ALS trial protocol

Frontiers in Neurology2022-09-2723 citations

Targeting metabolism to treat multiple sclerosis

Neural Regeneration Research2020-09-233 citations